About
Pipeline & Research
NEWS & MEDIA
Investors
Careers
Contact Us

Select Page

BeyondSpring PROTECTIVE-2 Phase 3 Trial Topline Results Update

November 17, 2020

11.16.2020

BeyondSpring PROTECTIVE-2 Phase 3 Trial Topline Results Update

View webcast

Search for:

RECENT NEWS ARTICLES

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
BeyondSpring Files 2023 Annual Report on Form 20-F

RECENT MEDIA COVERAGE

Seeking Alpha: BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC
IO360: Developing a Molecule to Help Patients Respond to Immunotherapy
TD Ameritrade Watch List
Managing Chemotherapy Toxicities for Improved Patient Outcomes
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
Seed Therapeutics blossoms in an $800M deal with Lilly
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy

Investor Contact
IR@beyondspringpharma.com

Media Contact
PR@beyondspringpharma.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

Who We Are
Management Team
Scientific Advisors
Board of Directors

PIPELINE & RESEARCH

Pipeline Overview
Plinabulin
Protein Degradation
Other Pipeline
Posters & Publications
Collaboration
Expanded Access Policy

Stock Overview
Events & Presentations
Financials & Filings
Corporate Governance

Job Opportunities

NEWS & MEDIA

Press Releases
Media Coverage

BeyondSprings Inc LinkedIn

BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved. Privacy Notice | Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.Ok Privacy policy